NOTCH1 combined with chemotherapy synergistically inhibits triple-negative breast cancer

Figure 5 Knockdown of NOTCH1 decreases NT5E to enhance the chemosensitivity of triple-negative breast cancer cells to cisplatin. A: Cisplatin IC₅₀ value analysis showing that re-expression of NT5E in NOTCH1-knockdown cells increased the resistance to cisplatin (IC₅₀ = 17.35 μM); B: CCK-8 assay showing that knockdown of NOTCH1 combined with cisplatin treatment inhibits cell proliferation, but this effect is reversed by NT5E overexpression; C: TUNEL assay showing that knockdown of NOTCH1 combined with cisplatin treatment significantly increases the apoptosis of cells, but this effect is reversed by NT5E overexpression. ^aP < 0.001.